TY - JOUR
T1 - In vitro growth and maturation of primordial follicles and immature oocytes
AU - Telfer, Evelyn E
AU - Andersen, Claus Yding
N1 - Copyright © 2021 American Society for Reproductive Medicine. All rights reserved.
PY - 2021/5
Y1 - 2021/5
N2 - Cryopreservation of ovarian tissue to preserve the fertility of girls and young women at high risk of sterility is now widely practiced. Pieces of cryopreserved ovarian cortex can be thawed and autografted to restore fertility, but because of the risks of reintroduction of the cancer, transplantation may not be possible for girls and women with blood-borne leukemias or cancers with a high risk of ovarian metastasis. Cryopreserved ovarian tissue contains mainly primordial follicles but also provides access to immature oocytes from small antral follicles, which may be matured in vitro to provide an additional source of mature oocytes. So in cases in which transplantation is contraindicated, fertility restoration could be safely achieved in the laboratory either by in vitro maturation (IVM) of oocytes aspirated from growing follicles or by the complete in vitro growth (IVG) and maturation (IVM) of primordial follicles to produce fertile metaphase II (MII) oocytes. The development of IVM and IVG methods to support all stages of oocytes available within ovarian tissue will maximize the potential for all patients undergoing fertility preservation.
AB - Cryopreservation of ovarian tissue to preserve the fertility of girls and young women at high risk of sterility is now widely practiced. Pieces of cryopreserved ovarian cortex can be thawed and autografted to restore fertility, but because of the risks of reintroduction of the cancer, transplantation may not be possible for girls and women with blood-borne leukemias or cancers with a high risk of ovarian metastasis. Cryopreserved ovarian tissue contains mainly primordial follicles but also provides access to immature oocytes from small antral follicles, which may be matured in vitro to provide an additional source of mature oocytes. So in cases in which transplantation is contraindicated, fertility restoration could be safely achieved in the laboratory either by in vitro maturation (IVM) of oocytes aspirated from growing follicles or by the complete in vitro growth (IVG) and maturation (IVM) of primordial follicles to produce fertile metaphase II (MII) oocytes. The development of IVM and IVG methods to support all stages of oocytes available within ovarian tissue will maximize the potential for all patients undergoing fertility preservation.
KW - Cryopreservation/methods
KW - Female
KW - Fertility Preservation/methods
KW - Humans
KW - In Vitro Oocyte Maturation Techniques/methods
KW - Oocytes/cytology
KW - Oogenesis/physiology
KW - Ovarian Follicle/cytology
KW - Ovarian Cryopreservation Follicle Culture
KW - in vitro fertilization (IVF)
KW - in vitro growth (IVG)
KW - Ovary
KW - in vitro growth and maturation (IVGM)
KW - In vitro follicle activation (IVA)
KW - in vitro maturation (IVM)
KW - Oocyte
UR - http://www.scopus.com/inward/record.url?scp=85103727108&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2021.03.004
DO - 10.1016/j.fertnstert.2021.03.004
M3 - Review
C2 - 33823993
SN - 0015-0282
VL - 115
SP - 1116
EP - 1125
JO - Fertility and Sterility
JF - Fertility and Sterility
IS - 5
ER -